Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.60 |
| ▸ | PPARA | Q07869 | 8/20 | 0.60 |
| ▸ | PPARG | P37231 | 5/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017243 | 0.92 | PPARD (0.60) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6052597 | 0.86 | PPARD (0.60) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5017180 | 0.84 | PPARD (0.60) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6532563 | 0.82 | PPARD (0.52) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6222387 | 0.81 | PPARD (0.48) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6223036 | 0.79 | PPARD (0.47) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL5016708 | 0.79 | PPARD (0.52) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5023890 | 0.79 | PPARD (0.41) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5859790 | 0.78 | PPARD (0.72) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL4467045 | 0.78 | PPARD (0.58) | PPARDPPARAPPARGFFAR1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.